Select sodium channel blockers have anti-diabetic effects

Select sodium channel blockers have anti-diabetic effects

(HealthDay)—Blockade of voltage-gated sodium channels (NaChs) in pancreatic α cells has anti-diabetic effects, according to research published online May 8 in Diabetes.

Arvinder K. Dhalla, Ph.D., of Gilead Sciences in Fremont, Calif., and colleagues tested the hypothesis that the mechanism by which ranolazine, a NaCh blocker approved for use in angina, exerts anti-diabetic effects is inhibition of glucagon release through blockade of sodium channels in α cells.

The researchers found that ranolazine causes blockade of in pancreatic α cells, inhibits their , and reduces the release of glucagon. The release of glucagon in human pancreatic islets is mediated by the Nav1.3 isoform. In animal models, ranolazine and a more selective sodium channel blocker, GS-458967, reduced postprandial and basal glucagon levels; these changes were associated with a reduction in hyperglycemia.

"The findings from the present study suggest that inhibition of α-cell INa could become an attractive drug target for combination with other classes of anti-diabetic agents," the authors write.

More information: Abstract
Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Researchers make exciting discoveries in non-excitable cells

Oct 17, 2013

It has been 60 years since scientists discovered that sodium channels create the electrical impulses crucial to the function of nerve, brain, and heart cells—all of which are termed "excitable." Now researchers at Yale ...

Recommended for you

Higher HDL cholesterol may help protect against cancer

Sep 26, 2014

(HealthDay)—Higher levels of high-density lipoprotein cholesterol (HDL-C) are associated with a decreased risk of cancer among individuals with type 2 diabetes, according to a study published online Sept. ...

User comments